Celularity Inc. (CELU) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Celularity Inc. (CELU) Bundle
Gain mastery over your Celularity Inc. (CELU) valuation analysis with our cutting-edge DCF Calculator! Preloaded with real CELU data, this Excel template enables you to adjust forecasts and assumptions to accurately compute the intrinsic value of Celularity Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.1 | 14.3 | 21.3 | 18.0 | 22.8 | 24.4 | 26.1 | 27.9 | 29.8 | 31.9 |
| Revenue Growth, % | 0 | -32.48 | 49.43 | -15.75 | 26.68 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| EBITDA | -1.7 | -202.4 | -88.1 | 23.6 | -183.9 | -10.1 | -10.8 | -11.6 | -12.4 | -13.3 |
| EBITDA, % | -7.96 | -1417.6 | -412.98 | 131.19 | -807.81 | -41.59 | -41.59 | -41.59 | -41.59 | -41.59 |
| Depreciation | 6.2 | 8.2 | 8.8 | 9.4 | 9.3 | 10.8 | 11.5 | 12.3 | 13.2 | 14.1 |
| Depreciation, % | 29.25 | 57.25 | 41.33 | 52.17 | 40.95 | 44.19 | 44.19 | 44.19 | 44.19 | 44.19 |
| EBIT | -7.9 | -210.6 | -96.9 | 14.2 | -193.3 | -12.6 | -13.5 | -14.4 | -15.4 | -16.5 |
| EBIT, % | -37.21 | -1474.85 | -454.31 | 79.03 | -848.75 | -51.64 | -51.64 | -51.64 | -51.64 | -51.64 |
| Total Cash | .9 | 54.3 | 37.2 | 14.0 | .2 | 13.8 | 14.7 | 15.8 | 16.9 | 18.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 6.6 | 5.2 | 7.0 | 12.1 | 7.9 | 8.5 | 9.1 | 9.7 | 10.4 |
| Account Receivables, % | 0 | 45.87 | 24.53 | 38.75 | 53.22 | 32.47 | 32.47 | 32.47 | 32.47 | 32.47 |
| Inventories | 3.2 | 3.9 | 9.5 | 5.3 | 5.8 | 6.9 | 7.4 | 7.9 | 8.5 | 9.0 |
| Inventories, % | 15.28 | 26.96 | 44.76 | 29.53 | 25.26 | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 |
| Accounts Payable | .0 | 5.4 | 9.3 | 5.8 | 14.1 | 8.6 | 9.2 | 9.8 | 10.5 | 11.2 |
| Accounts Payable, % | 0.08929399 | 37.75 | 43.67 | 32.32 | 62.11 | 35.19 | 35.19 | 35.19 | 35.19 | 35.19 |
| Capital Expenditure | -31.6 | -27.8 | -6.2 | -5.2 | -4.0 | -13.4 | -14.4 | -15.4 | -16.5 | -17.6 |
| Capital Expenditure, % | -149.31 | -194.94 | -29.07 | -29.13 | -17.78 | -55.2 | -55.2 | -55.2 | -55.2 | -55.2 |
| Tax Rate, % | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 | -0.00509463 |
| EBITAT | -7.1 | -205.9 | -96.9 | 14.2 | -193.3 | -12.3 | -13.1 | -14.0 | -15.0 | -16.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -35.7 | -227.4 | -94.8 | 17.3 | -185.3 | -17.5 | -16.4 | -17.6 | -18.8 | -20.1 |
| WACC, % | 5.17 | 5.4 | 5.46 | 5.46 | 5.46 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -77.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -21 | |||||||||
| Terminal Value | -605 | |||||||||
| Present Terminal Value | -466 | |||||||||
| Enterprise Value | -543 | |||||||||
| Net Debt | 65 | |||||||||
| Equity Value | -608 | |||||||||
| Diluted Shares Outstanding, MM | 18 | |||||||||
| Equity Value Per Share | -34.12 |
What You Will Get
- Real Celularity Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Celularity’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Data: Celularity Inc.'s (CELU) detailed financial statements and projected forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Insights: Instantly view Celularity's (CELU) intrinsic value as it updates dynamically.
- Informative Visualizations: Interactive dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Celularity Inc. (CELU) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Celularity Inc.'s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose the Celularity Inc. (CELU) Calculator?
- Precision: Utilizes accurate Celularity financial data for reliable results.
- Adaptability: Built for users to easily experiment and adjust inputs as needed.
- Efficiency: Eliminate the complexities of creating a financial model from the ground up.
- Expert-Level: Crafted with the insight and usability expected by financial professionals.
- Intuitive: Designed for straightforward navigation, suitable for users without extensive financial modeling skills.
Who Should Use Celularity Inc. (CELU)?
- Investors: Enhance your portfolio decisions with insights from cutting-edge cellular therapies.
- Healthcare Analysts: Streamline your research with comprehensive data on innovative treatments.
- Consultants: Effortlessly modify presentations or reports to showcase the latest developments in cell-based medicine.
- Biotech Enthusiasts: Expand your knowledge of regenerative medicine through real-world applications and case studies.
- Educators and Students: Utilize it as a valuable resource in courses focused on biotechnology and healthcare innovation.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Celularity Inc. (CELU) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Celularity Inc. (CELU).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.